Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of “Moderate Buy” from Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and eighteen have issued a buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $298.09.

Several equities analysts recently issued reports on the stock. TD Cowen boosted their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a “buy” rating in a report on Monday, October 21st. Barclays raised their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Citigroup lifted their target price on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ALNY. Allspring Global Investments Holdings LLC lifted its position in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $26,000. Huntington National Bank grew its holdings in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Hollencrest Capital Management purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $29,000. Finally, Altitude Crest Partners Inc. bought a new stake in Alnylam Pharmaceuticals during the first quarter worth $30,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Trading Down 0.8 %

Shares of ALNY stock opened at $244.89 on Friday. The stock has a 50-day moving average of $273.54 and a 200-day moving average of $236.84. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market cap of $31.59 billion, a price-to-earnings ratio of -93.47 and a beta of 0.39. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.15 earnings per share. On average, equities research analysts forecast that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.